Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
O14894

UPID:
T4S5_HUMAN

ALTERNATIVE NAMES:
Tetraspan transmembrane protein L6H

ALTERNATIVE UPACC:
O14894; Q17RW9; Q6IB79

BACKGROUND:
The protein Transmembrane 4 L6 family member 5, alternatively named Tetraspan transmembrane protein L6H, is integral to lysosomal membrane sensing of arginine. It collaborates with MTOR and SLC38A9, facilitating arginine efflux and the subsequent activation of mTORC1. This activation is crucial for phosphorylating RPS6KB1 and EIF4EBP1. Additionally, TM4SF5 is instrumental in accelerating the cell cycle's G1/S phase progression and in the nuclear translocation of the CDK4-CCND1 complex, influenced by CDKN1B and RHOA/ROCK signaling pathways.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Transmembrane 4 L6 family member 5 unveils potential avenues for therapeutic interventions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.